|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis显示文摘 | Erica Villa Calogero Cammà Marco Marietta Monica Luongo Rosina Critelli Stefano Colopi Cristina Tata Ramona Zecchini Stefano Gitto Salvatore Petta Barbara Lei Veronica Bernabucci Ranka Vukotic Nicola De Maria Filippo Schepis Aimilia Karampatou Cristian Ca | 2012 | Gastroenterology2012，，5： | 5 |
| 2 | Female gender in the setting of liver transplantation显示文摘The evolution of liver diseases to end-stage liver disease or to acute hepatic failure, the evaluation process for liver transplantation, the organ allocation decisionmaking, as well as the post-transplant outcomes are different between female and male genders. Women's access to liver transplantation is hampered by the use of model for end-stage liver disease(MELD) score, in which creatinine values exert a systematic bias against women due to their lower values even in the presence of variable degrees of renal dysfunction. Furthermore, even when correcting MELD score for gender-appropriate creatinine determination, a quantifiable uneven access to transplant prevails, demonstrating that other factors are also involved. While some of the differences can be explained from the epidemiological point of view, hormonal status plays an important role. Moreover, the pre-menopausal and post-menopausal stages imply profound differences in a woman's physiology, including not only the passage from the fertile age to the non-fertile stage, but also the loss of estrogens and their potentially protective role in delaying liver fibrosis progression, amongst others. With menopause, the tendency to gain weight may contribute to the development of or worsening of pre-existing metabolic syndrome. As an increasing number of patients are transplanted for non-alcoholic steatohepatitis, and as the average age at transplant increases, clinicians must be prepared for the management of this particular condition, especially in post-menopausal women, who are at particular risk of developing metabolic complications after menopause. | Kryssia Isabel Rodríguez-Castro Eleonora De Martin Martina Gambato Silvia Lazzaro Erica Villa Patrizia Burra | 2014 | World Journal of Transplantation2014，4，4： | 2 |
| 3 | Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: Sequence analysis and therapeutic strategy显示文摘 | Monica Luongo Rosina Critelli Antonella Grottola Stefano Gitto Veronica Bernabucci Mirco Bevini Chiara Vecchi Giuliano Montagnani Erica Villa | 2014 | Journal of Clinical Virology2014，，： | 2 |
| 4 | Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy显示文摘 | Massimo Iavarone Giuseppe Cabibbo Fabio Piscaglia Claudio Zavaglia Antonio Grieco Erica Villa Calogero Cammà Massimo Colombo | 2011 | Hepatology2011，，6： | 2 |
| 5 | Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years显示文摘 | Mauro Manno Calogero Cammà Filippo Schepis Fabio Bassi Roberta Gelmini Francesco Giannini Francesca Miselli Antonella Grottola Ilva Ferretti Chiara Vecchi Marisa De Palma Erica Villa | 2004 | Gastroenterology2004，，3： | 1 |
| 6 | Influence of Age and Gender Before and After Liver Transplantation显示文摘 | Patrizia Burra Eleonora De Martin Stefano Gitto Erica Villa | 2013 | Liver Transpl2013，，2： | 1 |
| 7 | Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B显示文摘 | Prof. Erica Villa MD Antonella Grottola BSc Paola Buttafoco BSc Paolo Trande MD Annalisa Merighi BSc Nicoletta Fratti MD Yodit Seium MD Giorgio Cioni MD Federico Manenti MD | 1995 | Digestive Diseases and Sciences1995，，1： | 1 |
| 8 | Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years显示文摘 | Mauro Manno Calogero Cammà Filippo Schepis Fabio Bassi Roberta Gelmini Francesco Giannini Francesca Miselli Antonella Grottola Ilva Ferretti Chiara Vecchi Marisa De Palma Erica Villa | | Gastroenterology0，，： | 1 |
| 9 | Obese zebrafish: A small fish for a major human health condition显示文摘Obesity is becoming a silent worldwide epidemic, with a steady increase in both adults and children. To date, even though several drugs have been licensed for long-term obesity treatment, none of them are yet used in routine clinical practice. So far the only successful intervention has been behavioral therapy. A suitable and economic experimental model mimicking the human condition would therefore be extremely useful to evaluate preventive measures and novel treatments. Zebrafish are emerging as an important model system to study obesity and related metabolic disease. Remarkable similarities have been reported in lipid metabolism and the adipogenic pathway between zebrafish and mammals. Moreover, the zebrafish possesses a number of features—the relative inexpensiveness of animal husbandry, its optical transparency and the ability to produce a large number of offspring at low cost—that make it ideal for large-scale screening and for testing drugs and intervention. In this review, we summarize recent progress in using zebrafish as a model system to study obesity and obesity-related metabolic disorders. We describe several zebrafish models(in both larvae and adult animals) that develop obesity and non-alcoholic fatty liver disease(NAFLD) using different approaches, including gene manipulation, diet manipulation and modification of microbiota composition. For these models, we have outlined the specific aspects related to obesity and its development and we have summarized their advantages and limitations. | Francesca Faillaci Fabiola Milosa Rosina Maria Critelli Elena Turola Filippo Schepis Erica Villa | 2018 | Animal Models and Experimental Medicine2018，1，4： | 1 |
| 10 | Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C显示文摘 | Erica Villa Aimilia Karampatou Calogero Cammà Alfredo Di Leo Monica Luongo Anna Ferrari Salvatore Petta Luisa Losi Gloria Taliani Paolo Trande Barbara Lei Amalia Graziosi Veronica Bernabucci Rosina Critelli Paola Pazienza Maria Rendina Alessandro Antonell | 2011 | Gastroenterology2011，，3： | 1 |
| 11 | Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C显示文摘 | Elisabetta Cariani Rosina Critelli Cristina Rota Monica Luongo Tommaso Trenti Erica Villa | 2011 | Journal of Virological Methods2011，，1： | 1 |
| 12 | Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection显示文摘 | Elisabetta Cariani Erica Villa Cristina Rota Rosina Critelli Tommaso Trenti | 2011 | Clinical Chemistry and Laboratory Medicine2011，，8： | 1 |
| 13 | Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years显示文摘 | Mauro Manno Calogero Cammà Filippo Schepis Fabio Bassi Roberta Gelmini Francesco Giannini Francesca Miselli Antonella Grottola Ilva Ferretti Chiara Vecchi Marisa De Palma Erica Villa | 2004 | Gastroenterology2004，，3： | 1 |
| 14 | Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis显示文摘 | Erica Villa Calogero Cammà Marco Marietta Monica Luongo Rosina Critelli Stefano Colopi Cristina Tata Ramona Zecchini Stefano Gitto Salvatore Petta Barbara Lei Veronica Bernabucci Ranka Vukotic Nicola De Maria Filippo Schepis Aimilia Karampatou Cristian Ca | 2012 | Gastroenterology2012，，5： | 1 |
| 15 | Direct-acting antivirals and risk of hepatocellular carcinoma: from genetic signature to metabolic risk factors显示文摘Hepatocellular carcinoma(HCC)is the fifth most common malignancy and the second leading cause of cancerrelated death.Hepatitis C virus and mainly hepatitis C virus-related cirrhosis is the chief risk factor for HCC.Many direct-acting antivirals are available for the eradication of hepatitis C virus with remarkable results in terms of virological response and with optimal safety profile.Notably,some authors have suggested that viral eradication due to these new drugs might favor both occurrence and recurrence of HCC.The exact biological mechanisms of carcinogenesis in this specific setting have not been well identified,but it has been suggested that adjustments in immune surveillance and increase in vascular endothelial growth factor expression could have a chief role.Remarkably,after publication of many large studies and meta-analyses,we can affirm that there is no increased risk on a population basis.Nonetheless,on an individual basis,sustained virological response due to direct-acting antivirals may facilitate HCC onset in some specific subgroups of patients.Among them,we could point out patients with activated neoangiogenesis but also subjects with particularly severe metabolic imbalance. | Stefano Gitto Erica Villa | 2020 | Hepatoma Research2020，6，5： | 0 |
| 16 | Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women显示文摘AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus(HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure(7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNApositive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virological response(SVR)(HCV RNA undetectable at 24 wk of follow-up) rate of at least 20% could be obtained. The secondary objective was the evaluation of the percent of patients with negative HCV RNA at week 4(RVR), 8(RVR BOC), 12(EVR), or at the end-of-treatment(ETR) that reached SVR. To assess the relationship between SVR and clinical and biochemical parameters, multiple logistic regression analysis was used.RESULTS: After lead-in, only two patients had RVR; HCV-RNA was unchanged in all but 62% who had ≤1 log10 decrease. After Boceprevir, HCV RNA became undetectable at week 8 in 32/56(57.1%) and at week 12 in 41/56(73.2%). Of these, 53.8% and 52.0%, respectively, achieved SVR. Overall, SVR was obtained in 25/56(44.6%). SVR was achieved in 55% previous relapsers vs. 41% non-responders(P = 0.250), in 44% F0-F2 vs 54% F3-F4(P = 0.488), and in 11/19(57.9%) of patients with cirrhosis. At univariate analysis for baseline predictors of SVR, only previous response to antiviral therapy(OR = 2.662, 95%CI: 0.957-6.881, P = 0.043), was related with SVR. When considering 'on treatment' factors, 1 log10 HCV RNA decline at week 4(3.733, 95%CI: 1.676-12.658, P = 0.034) and achievement of RVR BOC(7.347, 95%CI: 2.156-25.035, P = 0.001) were significantly related with the SVR, although RVR BOC only(6.794, 95%CI: 1.596-21.644, P = 0.010) maintained significance at multivariate logistic regression analysis. Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively. Only six patients discontinued therapy. CONCLUSION: Boceprevir obtained high SVR response independent of previous response, RVR or baseline fibrosis or cirrhosis. RVR BOC was the only independent predictor of SVR. | Veronica Bernabucci Alessia Ciancio Salvatore Petta Aimilia Karampatou Laura Turco Silvia Strona Rosina Critelli Paola Todesca Caterina Cerami Caterina Sagnelli Mario Rizzetto Calogero Cammà Erica Villa | 2014 | World Journal of Gastroenterology2014，20，44： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员